Brief: Jiangsu Recbio Tech Says Application For Clinical Trial Of Adjuvanted Recombinant HPV 9-Valent Vaccine Accepted
12/02/2025 13:50
Feb 12 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* ACCEPTANCE OF APPLICATION FOR CLINICAL TRIAL OF ADJUVANTED
RECOMBINANT HPV 9-VALENT VACCINE REC604C BY NMPA CHINA
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares